Table 1 Characteristics of the patients in this study
Characteristics | N (%) or median (Q1, Q3) | |||
|---|---|---|---|---|
Patients without recurrent disease (N = 2065) | Patients with recurrent disease (179) | Overall (N = 2244) | ||
Demographic characteristics and comorbidities | ||||
Age, years | Â | 41.00 (33.00, 50.00) | 44.00 (35.50, 52.00) | 42.00 (33.00, 50.00) |
|  | ≤ 42.0 | 1127 (54.6) | 83 (46.4) | 1210 (53.9) |
|  | > 42.0 | 938 (45.4) | 96 (53.6) | 1034 (46.1) |
Sex | Male | 677 (32.8) | 78 (43.6) | 755 (33.6) |
| Â | Female | 1388 (67.2) | 101 (56.4) | 1489 (66.4) |
Race | Han | 1983 (96.0) | 171 (95.5) | 2154 (96.0) |
| Â | Others | 82 (4.0) | 8 (4.5) | 90 (4.0) |
Smoking | No | 1787 (86.5) | 147 (82.1) | 1934 (86.2) |
| Â | Yes | 278 (13.5) | 32 (17.9) | 310 (13.8) |
Alcohol drinking | No | 1702 (82.4) | 139 (77.7) | 1841 (82.0) |
| Â | Yes | 363 (17.6) | 40 (22.3) | 403 (18.0) |
Comorbidity of diabetes | No | 2000 (96.9) | 165 (92.2) | 2165 (96.5) |
| Â | Yes | 65 (3.1) | 14 (7.8) | 79 (3.5) |
Comorbidity of hypertension | No | 1424 (69.0) | 96 (53.6) | 1520 (67.7) |
| Â | Yes | 641 (31.0) | 83 (46.4) | 724 (32.3) |
Comorbidity of Hashimoto’s thyroiditis | No | 1898 (91.9) | 161 (89.9) | 2059 (91.8) |
| Â | Yes | 167 (8.1) | 18 (10.1) | 185 (8.2) |
Tumor-related variables | ||||
Histology | PTC | 2029 (98.3) | 178 (99.4) | 2207 (98.4) |
| Â | FV-PTC | 36 (1.7) | 1 (0.6) | 37 (1.6) |
Tumor diameter, mm | ≤ 10 | 1026 (49.7) | 67 (37.4) | 1093 (48.7) |
| Â | 10 to 20 | 707 (34.2) | 70 (39.1) | 777 (34.6) |
| Â | 20 to 40 | 289 (14.0) | 33 (18.4) | 322 (14.3) |
|  | > 40 | 43 (2.1) | 9 (5.0) | 52 (2.3) |
Tumor foci | Unifocality | 1550 (75.1) | 117 (65.4) | 1667 (74.3) |
| Â | Multifocality | 515 (24.9) | 62 (34.6) | 577 (25.7) |
Tumor location | Isthmus | 9 (0.4) | 0 (0.0) | 9 (0.4) |
| Â | Left | 788 (38.2) | 64 (35.8) | 852 (38.0) |
| Â | Right | 902 (43.7) | 73 (40.8) | 975 (43.4) |
| Â | Bilateral | 366 (17.7) | 42 (23.5) | 408 (18.2) |
ETE | No | 1385 (67.1) | 112 (62.6) | 1497 (66.7) |
| Â | Minimal | 151 (7.3) | 12 (6.7) | 163 (7.3) |
| Â | Extensive | 529 (25.6) | 55 (30.7) | 584 (26.0) |
BRAF mutation | Negative | 256 (12.4) | 24 (13.4) | 280 (12.5) |
| Â | Positive | 543 (26.3) | 49 (27.4) | 592 (26.4) |
| Â | Unknown | 1266 (61.3) | 106 (59.2) | 1372 (61.1) |
Tg, ng/mL | Â | 0.22 (0.08, 0.71) | 0.99 (0.12, 4.14) | 0.24 (0.09, 0.79) |
|  | < 1.08 | 1715 (83.1) | 90 (50.3) | 1805 (80.4) |
|  | ≥ 1.08 | 350 (16.9) | 89 (49.7) | 439 (19.6) |
LN-related variables | ||||
LN dissection | No | 9 (0.4) | 0 (0.0) | 9 (0.4) |
| Â | Central dissection | 1443 (69.9) | 94 (52.5) | 1537 (68.5) |
| Â | Lateral dissection | 613 (29.7) | 85 (47.5) | 698 (31.1) |
Number of LN dissected | Â | 10 (5, 20) | 13 (7, 30) | 10 (5, 20) |
|  | < 21 | 1579 (76.5) | 108 (60.3) | 1687 (75.2) |
|  | ≥ 21 | 486 (23.5) | 71 (39.7) | 557 (24.8) |
ENE | No | 1985 (96.1) | 160 (89.4) | 2145 (95.6) |
| Â | Yes | 80 (3.9) | 19 (10.6) | 99 (4.4) |
LNR, % | Â | 27.78 (8.69, 50.00) | 35.71 (23.31, 55.05) | 28.57 (9.63, 50.00) |
|  | < 22.70 | 891 (43.1) | 42 (23.5) | 933 (41.6) |
|  | ≥ 22.70 | 1174 (56.9) | 137 (76.5) | 1311 (58.4) |
N stage | N0 | 484 (23.4) | 23 (12.8) | 507 (22.6) |
| Â | N1a | 1093 (52.9) | 80 (44.7) | 1173 (52.3) |
| Â | N1b | 488 (23.6) | 76 (42.5) | 564 (25.1) |
Metabolic and inflammatory markers | ||||
BMI, kg/m2 | < 18.5 | 120 (5.8) | 6 (3.4) | 126 (5.6) |
| Â | 18.5 to 24.0 | 1141 (55.3) | 91 (50.8) | 1232 (54.9) |
| Â | 24.0 to 28.0 | 637 (30.8) | 55 (30.7) | 692 (30.8) |
|  | ≥ 28.0 | 167 (8.1) | 27 (15.1) | 194 (8.6) |
Triglyceride, mmol/L | Â | 1.70 (1.70, 2.58) | 1.63 (1.14, 2.43) | 1.70 (1.70, 2.57) |
|  | < 2.30 | 1428 (69.2) | 126 (70.4) | 1554 (69.3) |
|  | ≥ 2.30 | 637 (30.8) | 53 (29.6) | 690 (30.7) |
Cholesterol, mmol/L | Â | 6.12 (5.32, 6.97) | 6.34 (5.47, 7.17) | 6.14 (5.34, 6.97) |
|  | < 6.20 | 1091 (52.8) | 85 (47.5) | 1176 (52.4) |
|  | ≥ 6.20 | 974 (47.2) | 94 (52.5) | 1068 (47.6) |
LDL, mmol/L | Â | 3.61 (3.01, 4.28) | 3.82 (3.07, 4.35) | 3.62 (3.01, 4.28) |
|  | < 4.10 | 1423 (68.9) | 110 (61.5) | 1533 (68.3) |
|  | ≥ 4.10 | 642 (31.1) | 69 (38.5) | 711 (31.7) |
HDL, mmol/L | Â | 1.55 (1.27,1.87) | 1.58 (1.30, 1.94) | 1.55 (1.27, 1.88) |
|  | < 1.00 | 164 (7.9) | 13 (7.3) | 177 (7.9) |
|  | ≥ 1.00 | 1901 (92.1) | 166 (92.7) | 2067 (92.1) |
NLR | Â | 1.59 (1.25, 2.08) | 1.60 (1.22, 2.06) | 1.59 (1.25, 2.08) |
|  | < 2.32 | 1741 (84.3) | 146 (81.6) | 1887 (84.1) |
|  | ≥ 2.32 | 324 (15.7) | 33 (18.4) | 357 (15.9) |
PLR | Â | 88.66 (67.61, 113.45) | 86.42 (67.98, 112.78) | 88.41 (67.58, 113.43) |
|  | < 116.18 | 1580 (76.5) | 144 (80.4) | 1724 (76.8) |
|  | ≥ 116.18 | 485 (23.5) | 35 (19.6) | 520 (23.2) |
PNI | Â | 55.85 (52.85, 58.85) | 55.75 (53.33, 58.95) | 55.83 (52.85, 58.90) |
|  | < 56.15 | 1076 (52.1) | 96 (53.6) | 1172 (52.2) |
|  | ≥ 56.15 | 989 (47.9) | 83 (46.4) | 1072 (47.8) |
LMR | Â | 7.68 (6.00, 9.96) | 7.65 (5.88, 9.80) | 7.67 (6.00, 9.95) |
|  | < 6.47 | 644 (31.2) | 65 (36.3) | 709 (31.6) |
|  | ≥ 6.47 | 1421 (68.8) | 114 (63.7) | 1535 (68.4) |
ATA risk stratification | ||||
| Â | Low risk | 314 (15.2) | 14 (7.8) | 328 (14.6) |
| Â | Intermediate risk | 1230 (59.6) | 104 (58.1) | 1334 (59.4) |
| Â | High risk | 521 (25.2) | 61 (34.1) | 582 (25.9) |